Literature DB >> 9163877

Characterization of the proliferation state in canine mammary tumors by the standardized AgNOR method with postfixation and immunohistologic detection of Ki-67 and PCNA.

C V Löhr1, J P Teifke, K Failing, E Weiss.   

Abstract

Paraffin-embedded tissue sections of 96 surgically removed mammary tumors from female dogs were analyzed for their proliferation state using three different methods. The AgNOR method, originally developed by Ploton and coworkers in 1986, modified and standardized by the AgNOR committee, is an easy, inexpensive silver-staining procedure used to determine cell proliferation and prognosis of various tumors. Due to the standardized staining protocol of the AgNOR method and a postfixation step, results obtained were of excellent quality for image-analysis processing. The growth fraction was evaluated by counting of immunohistologically positive-stained cells for Ki-67 or proliferating-cell nuclear antigen (PCNA). The values determined were, in general, lower with Ki-67 (MIB1) than with PCNA (PC10). Nevertheless, the labeling indices of these antigens correlated significantly (P < 0.001). Though the differences of the means between the tumor groups according to the classification system of the World Health Organization were significant for all three investigated methods (P < 0.001), there was a considerable overlap between the tumor groups concerning all investigated parameters. An exploratory data analysis (multivariate analysis) as performed to evaluate the prognostic relevance of the three methods including further anamnestic, clinical, gross, and histopathologic variables. Besides the histopathologic diagnosis (survival P < 0.001; survival time P < 0.05; reappearance of tumor growth P < 0.05), only the PCNA-labeling index (time until reappearance of tumor growth P < 0.001) was of prognostic significance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9163877     DOI: 10.1177/030098589703400306

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  6 in total

1.  Tarantula cubensis extract alters the degree of apoptosis and mitosis in canine mammary adenocarcinomas.

Authors:  Nilgun Gultiken; Tolga Guvenc; Duygu Kaya; Ali Reha Agaoglu; Serhan Serhat Ay; Ibrahim Kucukaslan; Birten Emre; Murat Findik; Sabine Schäfer-Somi; Selim Aslan
Journal:  J Vet Sci       Date:  2014-12-24       Impact factor: 1.672

2.  3D chick embryo chorioallantoic membrane model as an in vivo model to study morphological and histopathological features of feline fibrosarcomas.

Authors:  Katarzyna Zabielska-Koczywąs; Agata Wojtkowska; Izabella Dolka; Anna Małek; Magdalena Walewska; Anna Wojtalewicz; Artur Żbikowski; Roman Lechowski
Journal:  BMC Vet Res       Date:  2017-06-26       Impact factor: 2.741

3.  Prognostic efficacy of the human B-cell lymphoma prognostic genes in predicting disease-free survival (DFS) in the canine counterpart.

Authors:  Mohamad Zamani-Ahmadmahmudi; Sina Aghasharif; Keyhan Ilbeigi
Journal:  BMC Vet Res       Date:  2017-01-09       Impact factor: 2.741

Review 4.  Current biomarkers of canine mammary tumors.

Authors:  Ilona Kaszak; Anna Ruszczak; Szymon Kanafa; Kamil Kacprzak; Magdalena Król; Piotr Jurka
Journal:  Acta Vet Scand       Date:  2018-10-29       Impact factor: 1.695

5.  Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines.

Authors:  Michela Levi; Roberta Salaroli; Federico Parenti; Raffaella De Maria; Augusta Zannoni; Chiara Bernardini; Cecilia Gola; Antonio Brocco; Asia Marangio; Cinzia Benazzi; Luisa Vera Muscatello; Barbara Brunetti; Monica Forni; Giuseppe Sarli
Journal:  BMC Vet Res       Date:  2021-01-18       Impact factor: 2.741

6.  Identification of prognostic factors in canine mammary malignant tumours: a multivariable survival study.

Authors:  Andreia A Santos; Célia C Lopes; Jorge R Ribeiro; Liliana R Martins; Joana C Santos; Irina F Amorim; Fátima Gärtner; Augusto J Matos
Journal:  BMC Vet Res       Date:  2013-01-04       Impact factor: 2.741

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.